Abstract
Projecting future drug expenses is never an easy task. This year, Tichy et al1 provide key projections that will be needed now more than ever. This year health systems will not only face unprecedented financial challenges due to the coronavirus disease 2019 (COVID-19) pandemic; they may also be facing operational challenges. The section of the ASHP Foundation’s 2020 Pharmacy Forecast report regarding “black swans” (rare events with serious consequences, as popularized by Taleb2) noted that few health-system pharmacy departments had a strategic planning process in place to successfully deal with such an event.3 Meeting the patient surge and drug shortage challenges posed by the COVID-19 pandemic in addition to planning for costly new pharmaceuticals will test even the most robust organizations.